Plymate S R, Stutz F H, Fariss B L
J Clin Oncol. 1984 Jun;2(6):652-4. doi: 10.1200/JCO.1984.2.6.652.
It has been suggested that the level of sex hormone binding globulin (SHBG) is a better predictor of response of breast cancer to hormone treatment than the measurement of estrogen receptor (ER). However, no correlation of SHBG with ER status has been shown. To define the relationship between SHBG and the ER, the following study was undertaken. Fifty women with breast cancer and known ER status had SHBG measured by dextran-coated charcoal saturation analysis. The mean SHBG in all ER-positive patients was 20.7 +/- 2.4 (ng DHT bound/mL) and in all ER-negative patients was 11.5 +/- 2.0 (p less than 0.01). The mean premenopausal level of SHBG was 22.2 +/- 3.8 ng/mL and postmenopausal level was 20.0 +/- 5.7 ng/mL. There was no significant difference between these groups. ER-positive patients on tamoxifen had a SHBG of 29.8 +/- 9 ng/mL and ER-negative subjects on tamoxifen had a mean SHBG level of 8.3 +/- 3.4 ng/mL, p less than 0.01. ER-positive patients have a higher SHBG level than ER-negative patients; furthermore, this difference between ER-positive and ER-negative subjects was further demarcated by changes in SHBG after the subjects had been placed on tamoxifen.
有人提出，与雌激素受体（ER）检测相比，性激素结合球蛋白（SHBG）水平能更好地预测乳腺癌对激素治疗的反应。然而，尚未发现SHBG与ER状态之间存在相关性。为了明确SHBG与ER之间的关系，进行了以下研究。对50名已知ER状态的乳腺癌女性患者，采用葡聚糖包被活性炭饱和分析法测定SHBG。所有ER阳性患者的SHBG均值为20.7±2.4（结合双氢睾酮的纳克数/毫升），所有ER阴性患者的SHBG均值为11.5±2.0（p<0.01）。SHBG的绝经前平均水平为22.2±3.8纳克/毫升，绝经后水平为20.0±5.7纳克/毫升。这些组之间无显著差异。服用他莫昔芬的ER阳性患者的SHBG为29.8±9纳克/毫升，服用他莫昔芬的ER阴性受试者的SHBG平均水平为8.3±3.4纳克/毫升，p<0.01。ER阳性患者的SHBG水平高于ER阴性患者；此外，在受试者服用他莫昔芬后，SHBG的变化进一步区分了ER阳性和ER阴性受试者之间的这种差异。
